CSL Limited (CSLLY)
The price, the headline numbers and the latest news, in one place.
CSL Limited (CSLLY) Stock Price, Analysis & Data
No data available
| Bid | 31.65 |
| Market Cap | 60.7B |
| Revenue (ttm) | 15.8B |
| Net Income (ttm) | -2.58B |
| 0.09 | |
| -1.35 | |
| n/a | |
| 18.2 | |
| P/B (ttm) | 4.10 |
| P/S (ttm) | 3.84 |
| Earnings Date | Feb 9, 2027 |
| Ask | 31.7 |
| Volume | 19,874 |
| Avg. Volume (20D) | 307,466 |
| Open | 31.56 |
| Previous Close | 31.30 |
| Day's Range | 31.56 - 31.87 |
| 52-Week Range | 16.01 - 36.28 |
| Analyst | Hold |
| Price Target | 32 (0.95%) |
| Dividends | $0.72 (2.31%) |
| Ex-Dividend Date | Sep 10, 2026 |
About CSLLY
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqi...
Financial Performance
In 2026, CSL's revenue was 15.7B, an increase of 1.74% compared to the previous year's 15.43B. Earnings were -2.58B, a decrease of -185.91%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CSLLY stock is "Hold". The 12-month stock price forecast is 32, which is upside of 0.95% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
Analysts project revenue of ... Upgrade
